Regarding therapeutic approaches, recent data [78] have led to the approval of sotatercept, a TGF-β signaling inhibitor for PH, by the FDA; this agent was previously shown to improve anemia and ineffective erythropoiesis in thalassemic patients [79]. Here, TGFB1 is linked to anemia (phenotype).